載入中
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
收盤時
US$0.7849
−US$0.0091 · -1.15%
盤中時間採用ET。市場資料可能有所延遲。
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
日內區間
目前US$0.7849
52週區間
目前US$0.7849
盤中時間採用ET。市場資料可能有所延遲。
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
日內區間
目前US$0.7849
52週區間
目前US$0.7849
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 1000 USD | — | — | — | — |
| 毛利 | −1000 USD | — | — | — | — |
| 研究與開發 | 1102.9萬 USD | 1424.8萬 USD | 3991 USD | 1.8萬 USD | 1.7萬 USD |
| 銷售、一般及管理費用 | 1090.2萬 USD | 1386.4萬 USD | 1.14萬 USD | 9680 USD | 9597 USD |
| 營業費用 | 2193萬 USD | 6511.2萬 USD | 1.63萬 USD | 2.76萬 USD | 2.66萬 USD |
| 利息收入 | — | 40萬 USD | 600 USD | — | — |
| 折舊和攤銷 | 1000 USD | 6.3萬 USD | 11.9萬 USD | 16.9萬 USD | 12.1萬 USD |
| 營業利益 | −2193.1萬 USD | −6511.2萬 USD | −1.63萬 USD | −2.76萬 USD | −2.66萬 USD |
| 淨利 | −4987.1萬 USD | −6288.3萬 USD | −1.57萬 USD | −2.73萬 USD | −2.62萬 USD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
